Innovent Biologics

October 15, 2019

Rituxan Biosimilar IBI301 Shows Similar Safety, Efficacy to Original in B-cell Lymphomas, Trials Show

News

IBI301, a biosimilar to Rituxan (rituximab), has a similar response rate to the original compound in people with B-cell lymphomas, and behaves similarly inside the body, preliminary results of two trials ... Read more

June 11, 2019

Tyvyt Effective, Safe in Previously Treated Patients with Hodgkin’s Lymphoma, Phase 2 Trial Shows

News

Treatment with Tyvyt (sintilimab injection) was found safe and eased the tumor burden or led to cancer disappearance in nearly 3 out of 10 patients with relapsed or refractory classical ... Read more

May 23, 2019

IBI301 (Biosimilar of Rituxan) Meets Primary Endpoints in 2 Clinical Trials in China for B-cell Lymphomas

News

IBI301, a biosimilar of Rituxan (rituximab), behaves similarly in the body and has a similar efficacy as the original product in patients with B-cell cancers, according to results from two ... Read more

January 18, 2019

Tyvyt, PD-1 Inhibitor Newly Approved in China, Showed Efficacy Similar to Opdivo and Keytruda, Trial Data Show

News

The immune checkpoint inhibitor Tyvyt (sintilimab injection) reduced tumor burden in eight out of 10 people with relapsed or refractory classic Hodgkin’s lymphoma taking part in a Phase 2 clinical ... Read more

January 8, 2019

Tyvyt Approved in China for Previously Treated Classical Hodgkin’s Lymphoma

News

Tyvyt (sintilimab injection), an immune checkpoint inhibitor jointly developed by Innovent Biologics and Eli Lilly and Company in China, is now available as a therapy for patients with classical Hodgkin’s lymphoma who failed to respond ... Read more

July 9, 2018

Sintilimab Safe, Effective for Relapsed or Refractory Hodgkin’s Lymphoma Patients, Phase 2 Trial Shows

News

Sintilimab (IBI308), an immunotherapy candidate, was found to be safe and completely eliminated tumors in one-fourth of Chinese patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL) treated in a Phase 2 ... Read more